No connection

Search Results

SILO vs XWEL

SILO
Silo Pharma, Inc.
BEARISH
Price
$0.52
Market Cap
$8.4M
Sector
Healthcare
AI Confidence
95%
XWEL
XWELL, Inc.
BEARISH
Price
$1.14
Market Cap
$9.0M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
SILO
--
XWEL
--
Forward P/E
SILO
-0.74
XWEL
-0.43
P/B Ratio
SILO
1.09
XWEL
-1.04
P/S Ratio
SILO
116.19
XWEL
0.31
EV/EBITDA
SILO
-0.1
XWEL
-3.37

Profitability

Gross Margin
SILO
38.57%
XWEL
25.7%
Operating Margin
SILO
-4363.27%
XWEL
-45.07%
Profit Margin
SILO
0.0%
XWEL
-58.17%
ROE
SILO
-74.56%
XWEL
--
ROA
SILO
-35.63%
XWEL
-31.98%

Growth

Revenue Growth
SILO
0.0%
XWEL
-4.2%
Earnings Growth
SILO
--
XWEL
--

Financial Health

Debt/Equity
SILO
--
XWEL
--
Current Ratio
SILO
11.36
XWEL
0.46
Quick Ratio
SILO
10.55
XWEL
0.33

Dividends

Dividend Yield
SILO
--
XWEL
--
Payout Ratio
SILO
0.0%
XWEL
0.0%

AI Verdict

SILO BEARISH

SILO exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company is currently pre-revenue or stagnant (0% YoY growth) with an unsustainable operating margin of -4363.27%. While a high current ratio of 11.36 suggests a temporary cash runway, the long-term trajectory is severely negative with a 5-year price decline of 96%. The recent 1-month price spike appears to be speculative volatility rather than a fundamental turnaround.

Strengths
Strong short-term liquidity (Current Ratio: 11.36)
Price/Book ratio near 1.09 suggests the stock is trading close to its accounting value
Recent short-term price momentum (+60.9% in 1 month)
Risks
Extreme fundamental weakness (Piotroski F-Score 0/9)
Zero revenue growth (YoY and Q/Q)
Massive operating losses (-4363.27% operating margin)
XWEL BEARISH

XWEL exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -1.04, indicating negative shareholder equity. The company is facing a liquidity crisis with a Current Ratio of 0.46 and a Quick Ratio of 0.33, suggesting it cannot meet its short-term obligations. While there has been a speculative 1-year price recovery and recent EPS 'beats,' these are relative to deeply negative expectations and do not offset the fundamental insolvency risks. The combination of declining revenue (-4.20% YoY) and negative margins makes the current valuation unsustainable.

Strengths
Low Price-to-Sales ratio (0.31) suggests the market has already priced in significant failure
Recent quarterly EPS surprises have been positive (beating negative estimates)
Short-term 1-year price performance shows speculative interest (+48%)
Risks
Extreme bankruptcy risk indicated by Piotroski F-Score of 1/9
Negative equity (P/B -1.04) indicates liabilities exceed assets
Severe liquidity shortage with a Current Ratio well below 1.0 (0.46)

Compare Another Pair

SILO vs XWEL: Head-to-Head Comparison

This page compares Silo Pharma, Inc. (SILO) and XWELL, Inc. (XWEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile